Literature DB >> 29426831

Cardiovascular risk factors and subclinical organ damage after hematopoietic stem cell transplantation in pediatric age.

Bianca Borchert-Mörlins1, Nima Memaran1, Martin Sauer2, Britta Maecker-Kolhoff2, Karl-Walter Sykora2, Ricarda Blöte1, Elena Bauer1, Bernhard M W Schmidt3, Anette Melk4, Rita Beier5.   

Abstract

Advances in allogeneic hematopoietic stem cell transplantation (HSCT) in malignant and non-malignant diseases result in more long-term survivors, in whom cardiovascular (CV) disease is one leading non-cancer cause of death. This study aimed to evaluate risk factors and subclinical CV organ damage in survivors after HSCT in pediatric age. We enrolled 64 children in a cross-sectional approach 3.3 ± 3.1 years after HSCT. Anthropometric data, laboratory values, office and 24-h ambulatory blood pressure monitoring (ABPM) were evaluated, showing a high prevalence of obesity, hypertension and dyslipidemia. CV organ damage was determined by non-invasive measurements of aortic pulse wave velocity (PWV), left ventricular mass index (LVMI), and carotid intima media thickness (IMT). Increased IMT and elevated PWV reflecting subclinical vascular damage were detected in 48% (IMT) and 6% (PWV) of our population. For IMT, physical activity had a positive impact and was worsened by time after HSCT. Our results show a surprisingly high rate of subclinical CV organ damage and classical risk factors. Therefore, diagnosis and management of well-known CV risk factors belong to clinical care after HSCT.

Entities:  

Mesh:

Year:  2018        PMID: 29426831     DOI: 10.1038/s41409-018-0104-x

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  2 in total

1.  Prevalence of Ototoxicity Following Hematopoietic Stem Cell Transplantation in Pediatric Patients.

Authors:  Kristen Gertson; Susan S Hayashi; Kathryn Trinkaus; Fei Wan; Robert J Hayashi
Journal:  Biol Blood Marrow Transplant       Date:  2019-09-05       Impact factor: 5.742

2.  Preventing the adverse cardiovascular consequences of allogeneic stem cell transplantation with a multi-faceted exercise intervention: the ALLO-Active trial protocol.

Authors:  Hayley T Dillon; Nicholas J Saner; Tegan Ilsley; David Kliman; Andrew Spencer; Sharon Avery; David W Dunstan; Robin M Daly; Steve F Fraser; Neville Owen; Brigid M Lynch; Bronwyn A Kingwell; Andre La Gerche; Erin J Howden
Journal:  BMC Cancer       Date:  2022-08-17       Impact factor: 4.638

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.